Peer-reviewed, open access journal

Menu

What is Cancer Immunology & Translational Research?

CITR is an international peer-reviewed, open-access journal focusing on cancer immunology and research that connects biological discoveries with translational and clinical applications.

Does the journal publish fundamental research?

Yes. Fundamental studies are welcome when they provide meaningful insight into cancer immunology and are relevant to the journal's scope.

Does CITR publish clinical research?

Yes. Clinically relevant research addressing cancer immunology, immunotherapy, biomarkers, treatment response, resistance, and patient outcomes is within scope.

Does the journal accept review articles?

Yes. CITR considers review articles, systematic reviews, meta-analyses, perspectives, commentaries, and other appropriate scholarly contributions.

Does payment affect acceptance?

No. Article-processing charges are separate from editorial evaluation and do not determine acceptance.

Does CITR accept computational research?

Yes. Computational, bioinformatic, systems-biology, AI, and multi-omics studies may be considered where they address relevant questions in cancer immunology or translational oncology.

Does CITR publish special collections?

Yes. The journal may establish focused collections around scientifically important and emerging areas of cancer immunology and translational research.